Cambrex Corporation (NYSE:CBM) provides products and services to accelerate the development and commercialization of branded and generic small molecule therapeutics. Cambrex supports its customers worldwide with R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record and strong expertise in various chemical technologies.
For generic drug companies, Cambrex supplies more than 70 APIs (including controlled substances) for pain management, cardiovascular, gastrointestinal, central nervous system, endocrine and respiratory indications. Cambrex manufactures these products using complex chemistry and technical expertise while maintaining its long-standing reputation of quality and reliability.
About the Audit
The audit on Cambrex Profarmaco site was performed on 15 April 2008. The Report is 25 pages long, excluding appendices. Including appendices the Report is 103 pages long.
The Audit Report provides information on the site facilities and covers a wide range of materials, including;
Acebutolol HCL, Alprazolam, Ambroxol HCL, Amiloride HCL, Amiodarone HCL, Bisacodyl, Bromazepam, Brotizolam, Chlordiazepoxide Base, Chlordiazepoxide HCL, Chlorothiazide, Cinoxacin, Clonazepam, Clorazepate Dipotassium, Clozapine, Cromolyn Sodium, Diazepam, Diltiazem HCL, Estazolam, Etizolam, Flunitrazepam, Flurazepam HCL, Flurazepam 2HCL, Glibenclamide, Glipizide, Hydrochlorothiazide, Labetalol HCL, Lorazepam, Lormetazepam, Medazepam, Metaproterenol Sulfate, Methychlothiazide, Midazolam Base, Midazolam HCL, Midazolam Maleate, Mitrazepam, Oxazepam, Picosulfate Sodium, Pranoprofen, Propafenone HCL, Salbutamol Sufate, Salbutamol Base, Sotalol HCl, Temazepam, Terbutaline Sulfate, Triazolam.